Dr Peter Thomas Gonnella, MD | |
119 Rockland St, Rockport, ME 04856-4002 | |
(207) 594-7901 | |
Not Available |
Full Name | Dr Peter Thomas Gonnella |
---|---|
Gender | Male |
Speciality | Internal Medicine - Infectious Disease |
Location | 119 Rockland St, Rockport, Maine |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1619073236 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | 12300 (Maine) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Peter Thomas Gonnella, MD 119 Rockland St, Rockport, ME 04856-4002 Ph: (207) 594-7901 | Dr Peter Thomas Gonnella, MD 119 Rockland St, Rockport, ME 04856-4002 Ph: (207) 594-7901 |
News Archive
Sunridge International, announced today that China's State Food and Drug Administration, (SFDA), had approved the firm's Pneumatic Trabeculoplasty (PNT) treatment in China.
The National Institutes of Health has awarded a $2.5 million grant to an IU School of Nursing researcher for a study that will examine whether computerized cognitive training exercises can improve memory and quality of life for heart failure patients.
Weight loss after menopause lowers circulating estrogen hormones in women, and because estrogen is directly related to breast cancer, weight loss is thought to decrease risk of breast cancer.
Astellas Pharma Inc. and Medivation, Inc. today announced that the U.S. Food and Drug Administration has accepted for review a supplemental New Drug Application (sNDA) that they have submitted for XTANDI (enzalutamide) capsules in metastatic castration-resistant prostate cancer (mCRPC), which includes findings from the Phase 2 TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication.
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.
› Verified 8 days ago
Peter H Bagley, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 6 Glen Cove Dr, Rockport, ME 04856 Phone: 207-301-8542 Fax: 207-301-5277 | |
Neil D. Smith, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 823 Commercial St, Rockport, ME 04856 Phone: 207-596-6599 | |
Mira Regina Olson, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 4 Glen Cove Dr Ste 10, Rockport, ME 04856 Phone: 207-301-5970 Fax: 207-301-5310 | |
Dr. Donald J Weaver, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 4 Glen Cove Dr, Ste 104, Rockport, ME 04856 Phone: 207-594-7705 Fax: 207-594-0543 | |
Eric Elton, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4 Glen Cove Dr Ste 10, Rockport, ME 04856 Phone: 207-301-5790 Fax: 207-301-5310 | |
Victoria Hoch, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 6 Glen Cove Dr, Rockport, ME 04856 Phone: 207-301-8000 | |
Andrew E. Filderman, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4 Glen Cove Dr Ste 107, Rockport, ME 04856 Phone: 207-594-4244 |